Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Current Ratio
-
The current ratio demonstrates fluctuations within the observed periods, generally fluctuating around a range between approximately 1.0 and 1.5. Initially, it showed a moderate increase from 1.11 to 1.32 early in 2020, followed by some decline towards the end of 2020. Throughout 2021 and 2022, the ratio stabilized with values mostly above 1.3, indicating a consistent ability to cover short-term liabilities with current assets. In 2023 and into 2024, the ratio moved between 1.25 and 1.47, showing relative stability but with minor variations. Overall, the trend reflects consistent liquidity management with no sharp declines, suggesting stable working capital practices during these periods.
- Quick Ratio
-
The quick ratio followed a similar but more volatile pattern compared to the current ratio, ranging roughly between 0.58 and 0.93 over the time frame. It experienced a sharp initial rise in mid-2020 from 0.66 to 0.84 but dipped at the end of that year to 0.58. Subsequently, it exhibited periods of recovery, peaking near 0.9 during late 2022. However, the ratio saw dips often around mid-year 2023 and early 2024, decreasing towards the lower end of this range again. The fluctuations indicate variability in liquid assets excluding inventory relative to current liabilities. Despite this, the ratio's values above 0.5 suggest a fairly adequate quick liquidity position over the evaluated quarters.
- Cash Ratio
-
The cash ratio showed more pronounced variability across the quarters with values from a low of 0.22 to a high of about 0.54. Early 2020 and 2021 showed dips to the low 0.3 range, followed by intermittent recoveries, reaching near 0.5 by year-end 2022. The ratio then declined again entering 2023, hitting lows around 0.22 to 0.28 in early to mid-2024, before a return to moderate levels close to 0.4 to 0.5 in the subsequent quarters. These swings imply changing levels of cash and cash equivalents relative to current liabilities, reflecting a more conservative or varying cash holding strategy. Periods of lower cash ratio highlight tighter immediate liquidity availability compared to overall current assets.
Current Ratio
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Current assets | |||||||||||||||||||||||||||||
Current liabilities | |||||||||||||||||||||||||||||
Liquidity Ratio | |||||||||||||||||||||||||||||
Current ratio1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Current Ratio, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Current Assets
- The current assets demonstrate an overall upward trend over the examined periods, rising from $26,174 million in March 2020 to $37,065 million by June 2025. Short-term fluctuations occur, including a dip in mid-2023; however, this is followed by recovery and further growth through 2024 and into 2025. This indicates a generally improving liquidity position with increasing levels of assets readily available for short-term obligations.
- Current Liabilities
- Current liabilities show some variability but maintain a relatively stable range between approximately $21,000 million and $29,500 million. There is a notable peak at the end of 2020 ($27,327 million), followed by a decline and minor fluctuations in 2021 and 2022. A rise occurs again into 2024 before a slight decrease approaching mid-2025. This pattern suggests some management of short-term obligations with periodic increases possibly related to operational or market conditions.
- Current Ratio
- The current ratio values consistently exceed 1.0, indicating that current assets surpass current liabilities throughout the timeframe. Starting at 1.11 in early 2020, the ratio improves notably by mid-2020, stabilizing mostly above 1.3 with peaks around 1.46 to 1.47 at the end of 2022. Although minor declines are observed in some quarters, the ratio remains comfortably above 1.0, reflecting a healthy short-term financial position and an ability to cover liabilities with available assets. The ratio ends near 1.42 by mid-2025, supporting a sustained liquidity cushion.
Quick Ratio
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Cash and cash equivalents | |||||||||||||||||||||||||||||
Short-term investments | |||||||||||||||||||||||||||||
Accounts receivable, net of allowance for doubtful accounts | |||||||||||||||||||||||||||||
Total quick assets | |||||||||||||||||||||||||||||
Current liabilities | |||||||||||||||||||||||||||||
Liquidity Ratio | |||||||||||||||||||||||||||||
Quick ratio1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Quick Ratio, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in the company's liquidity position from March 31, 2020, through June 30, 2025.
- Total Quick Assets
- The total quick assets demonstrate some fluctuation over the observed period. Initially, quick assets increased from $15,614 million in March 2020 to a peak of $18,680 million by June 2020. This was followed by a decline to $15,778 million in September 2020. Subsequently, there was a general upward trend with occasional decreases, reaching a significant high of $22,642 million in December 2022. However, after this peak, total quick assets recorded a notable decrease in mid-2023, falling to $17,408 million in June 2023, before recovering again by mid-2024 to $25,974 million. Towards the end of the period, total quick assets experienced another decline, ending at $20,468 million in June 2025.
- Current Liabilities
- Current liabilities exhibited a somewhat volatile pattern. The liabilities decreased significantly from $23,483 million in March 2020 to $20,405 million in September 2020, then sharply rose to $27,327 million by December 2020. This increase was followed by variability around the $23,000 to $29,000 million range. The highest current liabilities were observed at $29,586 million in March 2025. The overall trend indicates substantial fluctuations without a clear consistent directional movement, reflecting potentially changing operational or financial obligations.
- Quick Ratio
- The quick ratio, representing liquidity, shows a correlation with the movements in quick assets and current liabilities. Starting below 1.0 at 0.66 in March 2020, it improved to 0.84 by June 2020 before falling sharply to 0.58 in December 2020 and March 2021. Following this, the ratio recovered progressively, displaying an upward trend to a high of 0.93 in December 2022. After a mid-2023 dip to 0.74, the quick ratio again rose, maintaining values around 0.8 to 0.88 for most of 2024 and into early 2025. Despite some fluctuations, the quick ratio generally remained below 1.0, indicating that current liabilities consistently exceeded quick assets throughout the period.
In summary, the liquidity position fluctuated notably, with quick assets and current liabilities experiencing substantial variability. The quick ratio generally remained below 1.0, reflecting constrained short-term liquidity. Peaks in quick assets around late 2022 suggest strong liquidity at that point, but subsequent declines highlight the need to monitor the company’s ability to meet short-term obligations closely. The increasing trend in current liabilities towards the end of the period also indicates potentially elevated working capital requirements or greater short-term debt levels, which may impact liquidity risk.
Cash Ratio
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Cash and cash equivalents | |||||||||||||||||||||||||||||
Short-term investments | |||||||||||||||||||||||||||||
Total cash assets | |||||||||||||||||||||||||||||
Current liabilities | |||||||||||||||||||||||||||||
Liquidity Ratio | |||||||||||||||||||||||||||||
Cash ratio1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Cash Ratio, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the available quarterly financial data reveals several notable trends in liquidity and short-term financial health indicators.
- Total Cash Assets
- Over the reported periods, total cash assets exhibit considerable fluctuations without a consistent upward or downward trajectory. Starting at 7,432 million US dollars in March 2020, cash assets peaked at 13,192 million US dollars by December 2022. Thereafter, a decline is observed, reaching as low as 5,619 million US dollars in March 2024, before recovering again to 14,593 million US dollars by June 2024. The most recent quarters depict a decrease again, ending near 8,622 million US dollars in June 2025. This pattern suggests periodic cash build-ups followed by draws, potentially reflecting operational cycles, investment activities, or financing activities impacting liquidity.
- Current Liabilities
- Current liabilities have generally remained elevated and show relative stability with some volatility during the periods. Starting from 23,483 million US dollars in March 2020, the figures slightly fluctuate around the 22,000 to 26,000 million US dollar range. Notable peaks include 29,586 million US dollars in March 2025. The data signals ongoing substantial short-term obligations, with occasional increases possibly due to temporary financing or operational needs.
- Cash Ratio
- The cash ratio, an indicator of the company's ability to cover short-term liabilities with cash assets, ranges between 0.22 and 0.54 across the periods reviewed. The ratio was lowest at 0.22 in March 2024, implying limited immediate liquidity to cover current liabilities, and highest at 0.54 in December 2022, reflecting a stronger liquidity position. The fluctuation demonstrates variability in liquidity management, with periods of relatively strong cash buffer alternating with tighter cash conditions.
In summary, the financial indicators suggest a company managing considerable current obligations with cash resources that vary substantially over time. Although the company has maintained cash ratios below 1.0 throughout, indicating that cash alone is insufficient to cover current liabilities, there are periods of improved liquidity. The cyclical nature of cash holdings coupled with stable current liabilities indicates active liquidity management possibly influenced by seasonal business activities or strategic financial decisions. Monitoring of cash reserves and continued focus on liquidity will remain important to ensure the company can meet its short-term commitments promptly.